Figure 1

Study subject enrollment and samples tested.^aOne patient enrolled to NMLD control cohort was removed for ineligibility due to new finding of liver mass with portal vein thrombosis on imaging after enrollment. CTC testing in this patient showed 20 CTCs per 7.5 mL peripheral blood. ^bOne sample each of CTC and FFPE did not yield sufficient DNA for sequencing. ^c4 primary and 3 metastatic tumor FFPE samples were available from 7 of the HCC cohort cases. Paired CTC WGA DNA and FFPE tumor tissue were available in 2 cases, one of which also had PBMC available. Paired FFPE tumor tissue and PBMC were available from 2 additional cases.